A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia–lymphoma

Autor: Shigeo Fuji, Kazuyoshi Ishii, Kaname Miyashita, Atae Utsunomiya, Takahiro Fukuda, Makoto Yoshimitsu, Tetsuya Eto, Hiroshi Fujiwara, Hirokazu Okumura, Hiroyasu Ogawa, Junji Tanaka, Yoshifusa Takatsuka, Yoshiko Atsuta, Kenji Ishitsuka, Akira Yokota, Akihito Yonezawa, Koji Kato, Junichi Tsukada, Akinori Nishikawa
Rok vydání: 2018
Předmět:
Zdroj: Bone Marrow Transplantation. 54:1266-1274
ISSN: 1476-5365
0268-3369
Popis: Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia-lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis, allo-HCT from an HLA haplo-identical donor yields promising outcomes for many diseases other than ATL. However, appropriate comparisons with other donor sources, especially cord blood and conventional HLA haplo-identical donors, are needed to validate the safety and efficacy of this modality. In this study, we retrospectively evaluated the outcome of allo-HCT without PTCY in patients with ATL registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database between 1985 and 2015. During that period, 46 patients received allo-HCT without PTCY and survivors were followed for a median of 2316.5 days (range: 220-3884 days). Although the estimated 1- and 5-year overall survival rates of the entire cohort were 34.5% and 17.7%, respectively, the cumulative 1- and 5-year non-ATL mortality rates of 41.3% and 55.8%, respectively, were high. The results of our study will serve as a platform for discussions of the safety and efficacy of haplo-HCT for future clinical trials in patients with ATL.
Databáze: OpenAIRE
Externí odkaz: